Objectives: If screening to find effective drugs is possible, the inhibition of proliferation using existing drugs can be a practical strategy to control the drug resistance of cancer. Development of a system-oriented strategy to find effective drugs was the main aim of this research. Results: Experimental assessments demonstrated that TRFBA improves the prediction of cancer cell growth in comparison with previous algorithms. The algorithm was then used to propose the system-oriented strategy to search drugs effective in limiting the growth rate of the cisplatin-resistant A2780 epithelial ovarian cancer cell.
| INTRODUCTION
Acquired drug resistance is a major problem to achieving successful cancer treatment, 1 and the development of drug resistance in cancer cells is accompanied by metabolic dysregulation and alteration 2 that may be therapeutically targetable. In fact, an altered metabolism supports different behaviours of drug-resistant cancer cells, and targeting cancer metabolism can be an approach to treating them. However, dysregulated metabolism in drug resistance has not been addressed in details and deserves further investigation. 3 Metabolic changes caused by a resistant state can be specified using omic technologies, and genome-scale metabolic network reconstructions (as a platform for interpreting omics data) can be used to study how changes affect the functional states of the network. 4, 5 In fact, the global human metabolic networks and several algorithms for integration of omics data 6, 7 have enabled systems biology approaches to study the metabolism of human diseases such as obesity, diabetes, inborn errors of metabolism and cancer. Specifically, metabolic models were used to reconstruct a generic metabolic model of cancerous cells, 8 compare metabolism of drug-resistant and -sensitive cancer cells, 2 study metabolic differences between healthy and cancerous cells and within cancerous cells, 9 and find therapeutic strategies. 10, 11 Identifying new drugs is a difficult task which requires much time, research and development before any new compound can be commercialized. 11 Thus, already available drugs may be applied for the treatment of drug resistance even though they are designed for other diseases. The use of existing drugs is very valuable because extensive information about both their therapeutic and side effects has already been discovered during the study for their approval. The therapeutic and side effects of a drug can be beneficial in treating cancer. 12 Considering the time and cost required for drug development, it would be particularly exciting if a systematic method could be applied to reveal all of the applications of a drug especially for combating complex diseases such as cancer. The development of such a systematic method can be helpful, especially clinically in reducing the development of drug resistance and for use in personalized medicine. In this research, transcriptomic data and a generic human metabolic reconstruction were integrated to propose a systematic and system-oriented method.
Over the years, various algorithms for integration of omics data and metabolic models have been presented that can be classified based on continuous or discrete restriction of reaction flux. 13 Recently, an algorithm named TRFBA (transcriptional regulated flux balance analysis)
has been presented that continuously restricts the rate of reaction(s)
supported by a metabolic gene. 14 This algorithm uses a constant parameter (C) to convert the expression levels to the upper bounds of the reactions. Implementation of TRFBA to estimate growth rates of Escherichia coli and Saccharomyces cerevisiae indicated a significant improvement in the quantitative prediction of growth in comparison with previously presented algorithms. Considering that the inhibition of cancer cell growth is the main aim of this research, TRFBA was selected to reconstruct cancer cell-specific models. To evaluate the capability of TRFBA, a data set for NCI-60 cancer cell lines was used and predictions of TRFBA were compared with two GIMME (Gene Inactivity Moderated by Metabolism and Expression) 15 and PRIME (Personalized ReconstructIon of Metabolic models) 16 ,17 algorithms previously used in cancer studies. The parameter C was adjusted using the sensitivity analysis proposed in the original paper.
Cisplatin is known as one of the most widely used drugs for the treatment of ovarian cancers, but resistance to this drug occurs in many cases 18 and relapse of disease with fully chemoresistant is observed for over 80% of treated patients. 19 Hence, cisplatin-resistant A2780 epithelial ovarian cancer as an important drug-resistant cancer was selected for more investigation in this research. Growth of cisplatin-resistant and -sensitive A2780 epithelial ovarian cancer cell lines was simulated using TRFBA to identify target genes. Given that C was set for the NCI-60 data set, a housekeeping gene (HKG) with the highest level of expression stability was selected to calibrate the expression levels of ovarian cancer cells. The Drugbank database 20 was screened to find inhibitors of the target genes. The ability of the identified drugs to prevent the growth of drug-resistant cancer cells was experimentally evaluated. used. Calculations were made in MATLAB software using the COBRA Toolbox. 24 The GLPK (GNU Linear Programming Kit) package was used to solve linear programming (LP) problems. 
| MATERIALS AND METHODS

| Model and computational methods
| Genome-scale model
| The linear form of TRFBA
| In silico simulation
The biomass reaction was used as an objective function to be maximized in all simulations. An RPMI (Roswell Park Memorial
Institute)-1640 medium was considered in all simulations. 8 An upper
bound of 1000 was considered for intercellular reactions, and lower bounds of −1000 and 0 were considered for intercellular reversible and irreversible reactions respectively.
Error rates for TRFBA predictions of growth for NCI-60 cancer cell lines were compared with those of GIMME and PRIME. For each cell line, predicted and experimental growth rates were used to calculate the relative error.
14 The GIMME implementation in the COBRA Toolbox was used. Gene expression cut-off value was set to the 25th
percentile of the given expression data, 13 and the required fraction of the original objective value was set to 90% of the maximum growth rate as in the original publication. An implementation of PRIME was provided with the original publication. 16 The algorithms were also implemented to predict the growth rate of cisplatin-resistant and -sensitive A2780 epithelial ovarian cancer cells in a batch culture.
| A system-oriented strategy to find effective drugs
According to Figure 1 , a two-stage strategy was used to screen genes and drugs. The input data include a generic human metabolic model and calibrated expression data. Single gene deletion analysis using TRFBA was carried out to find the genes affecting the growth of cisplatin-resistant and -sensitive cancer cells. In this analysis, the expression of each gene was set to zero, and then the growth rate was calculated using TRFBA. Genes that, upon removal, resulted in at least 1% growth reduction were determined to be target genes. Drugbank was checked for drugs that inhibit activation of the target genes. The drugs were prepared, and their capability to reduce the growth rate of cisplatin-resistant cancer cell was experimentally examined using MTT assay.
| Experimental materials and methods
| Materials
RPMI-1640 medium and fetal bovine serum (FBS) were purchased 
| Cell growth curves
Once the cell lines reached 80 to 90% of confluence, they were counted in a Neubauer chamber at 1:2 dilution with trypan blue dye exclusion. About 15 000 cells/well of each cell line were cultured on a 24-well plate and number of cells was measured every day for 8 days.
The growth rate for each cell line was determined by a non-linear regression curves analysis.
| Cell viability assay
The viability of cells (A2780, A2780-cis and HDF cell lines) was determined in the presence of drugs by the MTT (Sigma-Aldrich, USA)
assay. Briefly, the number of 5000 cells/well were seeded into 96-well plates and incubated at 37°C for 24 hours in a humidified atmosphere of 5% CO 2 . Then, the cells were incubated with freshly prepared drugs. They were incubated for 48 hours and then tested for viability. Calibrate the expression data using a stable HKG
MTT assay
TRFBA determined for more investigation. It should be mentioned that the optimum concentration of cisplatin was determined for sensitive cells because effect of this drug on proliferation of resistant cells was not significant.
| Combination therapy of drugs
The synergistic combination of drugs can reduce the frequency of acquired resistance. Furthermore, it can overcome toxicity and other adverse effects associated with high doses of a single drug. 26 Thus, the synergistic effect of selected drugs was assessed. To evaluate the effect of drug combinations on proliferation, the concentration of each drug (except cisplatin) that resulted in a 20% death rate in cisplatin-resistant cells was determined. For cisplatin, the concentration that resulted in a 20% death rate in cisplatin-sensitive cells was determined. Then, each pair of drugs with the determined concentrations was used for treatment, and MTT assays were performed. If the death of the resistant cancer cell was more than 40%, the drug pair was identified as a synergistic pair proper for use in combination therapies. Furthermore, synergistic effect was quantified using the synergism quotient (SQ) defined as the ratio of the effect of the combined treatment divided by the sum of the two individual treatments. 27,28 A SQ greater than one indicates that there is a synergistic effect, while a SQ less than one indicates an antagonistic effect and SQ close to one
indicates an additive effect.
| RESULTS
| Evaluation and validation
The capability of TRFBA to predict the growth rates of NCI-60 cell lines was assessed and compared with GIMME and PRIME. For each cell line, the predicted and experimental growth rates were used to calculate error of the growth rate. Sensitivity of the error with respect to the C values was analysed to find the optimal value of C. Figure 2A depicts the average error and variations in the error of NCI-60 cell lines. The variation is monotonic similar to the results for E. coli and S. cerevisiae data sets 14 and the optimal value of C is 0.00014 mmol gDCW
. This optimal value was used to indicate the distribution of error in Figure 2B . This figure demonstrates that TRFBA and PRIME are much better approaches than GIMME for integrating expression data with Recon 2 to predict growth rates.
TRFBA and PRIME continuously restrict reaction flux, while GIMME discretizes expression data into low-and high-expressed data and deletes reactions based on expression level. It should also be mentioned that the distribution of error for TRFBA was more appropriate than that of PRIME, although growth rate measurements were used by PRIME to determine reactions significantly correlated to growth rate.
| Growth prediction of the ovarian cancer cells
The experimental growth rates of ovarian cancer cells were determined based on the exponential curve fit of the cancer cell count against time same and equals to about 218.5. Hence, the expression levels of ovarian cancer cells were divided by 2.39 (218.5/91.31) to be calibrated.
Considering the ovarian cancers as two samples, PRIME found no reaction correlated to growth rate and was therefore not applicable for predicting growth. In fact, PRIME required many more samples to reconstruct a cell-specific model. Hence, the calibrated expression levels and experimental growth rates of ovarian cancer cells were added to the NCI-60 data set and these 62 sets of information were used to determine growth-associated reactions. Table 1 demonstrates that PRIME and GIMME over-predicted the growth rates of cancer cells and were unable to quantitatively estimate growth; however, predictions of PRIME were better than GIMME, and PRIME was able to predict more growth rate for resistant cells. The TRFBA prediction of growth for both resistant and sensitive cancer cells was comparable with the experimental data and this algorithm predicted the growth rates of resistant and sensitive cancer cells with relative error of 8 and 11%, respectively. In addition, TRFBA properly indicated that the growth rate of resistant cells is more than that of sensitive cells. These results indicate that TRFBA can properly control the uptake rates of other metabolites using expression data and can distinguish the differences between the expression data of two similar cancer cells. However, PRIME and GIMME do not have enough resolution power to appropriately recognize the effect of different expression data of ovarian cancer cells on growth.
| Finding effective drugs
The genes affecting the growth of ovarian cancer cells were identified using single gene deletion analysis by TRFBA. Inhibiting drugs effective on these genes were found from Drugbank and are presented in Table S2 . It can be seen that some drugs were originally applied for the treatment of diseases other than cancer.
Among the found drugs, nine available drugs including aciclovir, azathioprine, terbinafine, capecitabine, hyralazine, nitisinone, orlistat, sodium valproate and vigabatrin in addition to cisplatin were used to treat ovarian cancer cell lines, and their effect on the cell viability of HDF was also analysed. Some initial experiments were carried out to determine effective concentration of the studied drugs (data not shown). The optimum concentration of each found drug that resulted in the maximum inhibition of resistant cancer cell growth was specified and presented in Table 2 . The cisplatin concentration in Table 2 was determined for sensitive cancer cells because the effect of this drug on growth of A2780-cis was not significant.
The results of MTT test on A2780, A2780-cis and HDF cells using the optimum drug concentrations are shown in Figure 3 to evaluate the maximum capability of each drug to control growth of resistant cancer cells. Azathioprine, terbinafine, hydralazine and sodium valproate were found to be effective against the proliferation rates of resistant cells with cell viability of 47%, 54%, 44% and 72%. Furthermore, these drugs inhibit growth of sensitive cells and maximum death rate for HDF cells was 25%. Of these drugs, azathioprine is the only drug originally synthesized as a cancer drug. It hinders DNA synthesis by blocking the synthesis of purine, and thus inhibits the proliferation of cells. 32 Terbinafine, hydralazine and sodium valproate were originally synthesized as antifungal, anti-hypertensive and epilepsy drugs, respectively, and they inhibit the activation of SQLE, AOC3 and SLC25A20 genes respectively.
As expected, cisplatin reduced the viability of A2780 and HDF to 42% and 85.5%; its effect on A2780-cis was negligible. Figure 3 demonstrates Aciclovir is the only predicted effective drug that has no significant effect on the growth of cancer cells. The results presented in Table 3 
| Combination of the effective drugs
| DISCUSSION
The integration of transcriptomic data into a generic metabolic model using TRFBA was employed to automatically reconstruct cancer cell-specific models. Proposed method of data calibration using a stable HKG enabled the algorithm to use the optimal value of its parameters for all cell lines. The model was applied to find bottleneck genes for the growth of ovarian cancer cells that can be considered as drug targets. Screening for these targets indicated that inhibiting drugs were designed for some of these targets, even though they 
Cell death SQ
A2780-cis A2780 HDF
A2780-cis A2780
Azathioprine 
